The pathogenetic substantiation of the use of angiotensin-converting enzyme for the treatment of diabetic retinopathy

Riabina M.V.; Chesnokova N.B.; Okhotsimskaia T.D.; Kuznetsova T.P.

doi:https://doi.org/

Riabina M.V.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Chesnokova N.B.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Okhotsimskaia T.D.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Kuznetsova T.P.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

The pathogenetic substantiation of the use of angiotensin-converting enzyme for the treatment of diabetic retinopathy

Authors:

Riabina M.V., Chesnokova N.B., Okhotsimskaia T.D., Kuznetsova T.P.

More about the authors

Journal: Problems of Endocrinology. 2012;58(5): 37‑40

Read: 863 times

Download PDF (RU)

Contact the author

Table of contents

To cite this article:

Riabina MV, Chesnokova NB, Okhotsimskaia TD, Kuznetsova TP. The pathogenetic substantiation of the use of angiotensin-converting enzyme for the treatment of diabetic retinopathy. Problems of Endocrinology. 2012;58(5):37‑40. (In Russ.)

Использование инфографики авторами научных работ

Close metadata

Recommended articles:

Objective structural and functional monitoring of polypeptide retinal neuroprotective therapy in diabetic retinopathy. Russian Annals of Ophthalmology. 2024;(5):97-104

Diabetic retinopathy and pregnancy. Russian Annals of Ophthalmology. 2024;(6):145-151

The influence of demographic factors and major comorbidities on serum circulating regulatory microRNAs in patients with coronary artery atherosclerosis and thoracic aortic aneurysm: a single-center cohort study. Russian Journal of Cardiology and Cardiovascular Surgery. 2025;(2):174-182

The effect of vitrectomy on changes in molecular biomarker levels of the vitreous cavity in the early postoperative period in proliferative diabetic retinopathy. Russian Annals of Ophthalmology. 2025;(2):30-36

The effects of intraoperative use of angiogenesis inhibitors on outcomes and complication rates in the surgical treatment of proliferative diabetic retinopathy. Russian Annals of Ophthalmology. 2025;(2):44-50

Abstract:

The objective of the present work was to study visual functions, as well as changes in the systemic and local renin-angiotensin system before and after intake of the ACE inhibitor perindopril in 65 patients (130 eyes) presenting with diabetic retinopathy. The treatment caused the most pronounced changes in the patients with preproliferative diabetic retinopathy including the two-fold (p<0.05) decrease of ACE activity in the blood and its 7.5-fold (p<0.05) increase in the tears. These effects appear to be attributable to the action of perindopril on the levels of the proangiogenic factors known to be elevated in the patients with severe retinal ischemia. The treatment of patients with diabetic macular oedema with perindopril resulted in the decrease of the retinal thickness from 392.5±46.7 to 347.2±39.6 mcm in the absence of significant improvement in the acuteness of vision. All the patients experienced a significant reduction in the level of glycosylated hemoglobin.

Keywords:

diabetic retinopathy

renin-angiotensin system

ACE inhibitors

Authors:

Riabina M.V.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Chesnokova N.B.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Okhotsimskaia T.D.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Kuznetsova T.P.

FGBU Moskovskiĭ nauchno-issledovatel'skiĭ institut glaznykh bolezneĭ im. Gel'mgol'tsa Minzdrava RF, Moskva

Close metadata

References:

Balabolkin M.I. Diabetologiya. M: Meditsina 2000; 345.
Dedov I.I., Shestakova M.V. Sakharnyi diabet i arterial'naya gipertenziya. M: MIA 2006; 345.
Antonetti D.A., Klein R., Gardner T.W. Diabetic retinopathy. N Engl J Med 2012; 366: 13: 1227-1239.
Lang G.E. Diabetic retinopathy. Development in ophthalmology. Basel: Karger 2007; 39.
Opie L.N. Angiotensin-Converting Enzyme Inhibitors. The Advance Continues. New York: Author,s Publishing House 1999; 315.
Karpov Yu.A. Arterial'naya gipertoniya u bol'nykh sakharnym diabetom: osnovnye napravleniya lecheniya. Rus med zhurn 2001; 9: 24: 11-15.
Hammes H.P., Porta M. Experimental Approaches to Diabetic Retinopathy. Frontiers of Diabets. Basel: Karger 2010; 20.
Dancer A.H. Local renin-angiotesin system: the unanswered questions. Int J Biochem Cell Biol 2003; 35: 759-768.
Fletcher E.L., Phipps J.A., Ward M.M., Vessey K.A., Wilkinson-Berka J.L. The renin-angiotensin system in retinal health and disease: Its influence on neurons, glia and the vasculature. Prog Retin Eye Res 2010; 29: 4: 284-311.
Kohner E.M. The renin-angiotensin system and diabetic retinopathy. Klin Wochenschr 1992; 69: Suppl 29: 25-27.
Hammes H.P., Feng Y., Pfister F., Brownlee M. Diabetic Retinopathy: Targeting Vasoregression. Diabetes 2011; 60: 1: 9-16.
Pavlenko T.A. Angiotenzin-prevrashchayushchii ferment v tkanevykh strukturakh i zhidkikh sredakh glaza v norme i patologii, puti regulyatsii: Avtoref. dis. ... kand. med. nauk. M 2009.
Wilkinson-Berka J.L. Angiotensin and diabetic retinopathy. Int J Biochem Cell Biol 2006; 38: 5-6: 752-765.
Neroev V.V., Ryabina M.V., Okhotsimskaya T.D., Zueva M.V., Tsapenko I.V. O primenenii preparata "Perindopril" v lechenii bol'nykh diabeticheskoi retinopatiei. Vestn oftal'mol 2006; 4: 123: 4: 31-33.
Neroev V.V., Chesnokova N.B., Okhotsimskaya T.D., Ryabina M.V., Kost O.A., Nikol'skaya I.I., Pavlenko T.A. Aktivnost' angiotenzinprevrashchayushchego fermenta v krovi i sleze u bol'nykh s diabeticheskoi retinopatiei. Vestn oftal'mol 2006; 3: 122: 3: 11-14.
Altynbaev U.R. Prognozirovanie i profilaktika oslozhnenii khirurgicheskogo lecheniya proliferativnoi diabeticheskoi retinopatii: Avtoref. dis. ... kand. med. nauk. Ufa 2006.
Larsen M., Hommel E., Parving H.H., Lund-Andersen H. Protective effect of captopril on the blood-retina barrier in normotensive insulin-dependent diabetic patients with nephropathy and background retinopathy. Graefes Arch Clin Exp Ophthalmol 1990; 228: 505-509.
Chase H.P., Garg S.K., Harris S., Hoops S., Jackson W.E., Holmes D.L. Angiotensin-converting enzyme inhibitor treatment for young normotensive diabetic subjects: a two-year trial. Ann Ophthalmol 1993; 25: 284-289.
Chaturvedi N., Porta M., Klein R., Orchard T., Fuller J., Parving H.H., Bilous R., Sjolie A.K. for the DIRECT Programme Study Group: Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008; 372: 1394-1402.
Chaturvedi N., Sjolie A.-K., Stephenson J.M., Abrahamian H., Keipes M., Castellarin A., Rogulja-Pepeonik Z., Fuller J.H. the EUCLID Study Group: Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. Lancet 1998; 351: 28-31.